Switch to:

Beam Therapeutics Cash Flow from Financing

: $196.39 Mil (TTM As of Mar. 2020)
View and export this data going back to 2020. Start your Free Trial

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Mar. 2020, Beam Therapeutics received $192.51 Mil more from issuing new shares than it paid to buy back shares. It received $1.31 Mil from issuing more debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It spent $0.81 Mil on other financial activities. In all, Beam Therapeutics earned $193.01 Mil on financial activities for the three months ended in Mar. 2020.


Beam Therapeutics Cash Flow from Financing Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

* Premium members only.

Beam Therapeutics Annual Data
Dec17 Dec18 Dec19
Cash Flow from Financing 0.00 179.73 41.28

Beam Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20
Cash Flow from Financing Premium Member Only Premium Member Only 37.91 -0.02 2.69 0.70 193.01

Beam Therapeutics Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Beam Therapeutics's Cash from Financing for the fiscal year that ended in Dec. 2019 is calculated as:

Beam Therapeutics's Cash from Financing for the quarter that ended in Mar. 2020 is

Cash Flow from Financing(Q: Mar. 2020 )
=Net Issuance of Stock+Net Issuance of Debt+Net Issuance of Preferred Stock+Cash Flow for Dividends+Other Financing
=192.51+1.31+{NetIssuanceofpreferred_last}}+0+-0.80599999999998
=193.01

Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2020 was -0.02 (Jun. 2019 ) + 2.692 (Sep. 2019 ) + 0.699 (Dec. 2019 ) + 193.014 (Mar. 2020 ) = $196.39 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.


Beam Therapeutics  (NAS:BEAM) Cash Flow from Financing Explanation

Cash from financing contains five items:

1. Net Issuance of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. If this number is positive, it means that the company has received more cash from issuing shares than it has paid to buy back shares. If this number is negative, it means that company has paid more cash to buy back shares than it has received for issuing shares.

Beam Therapeutics's net issuance of stock for the three months ended in Mar. 2020 was $192.51 Mil. Beam Therapeutics received $192.51 Mil more from issuing new shares than it paid to buy back shares.

2. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Beam Therapeutics's net issuance of debt for the three months ended in Mar. 2020 was $1.31 Mil. Beam Therapeutics received $1.31 Mil from issuing more debt.

3. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Beam Therapeutics's net issuance of preferred for the three months ended in Mar. 2020 was $0.00 Mil. Beam Therapeutics paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

4. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Beam Therapeutics's cash flow for dividends for the three months ended in Mar. 2020 was $0.00 Mil. Beam Therapeutics received $0.00 Mil from paying cash dividends to shareholders.

5. Other Financing:
Money spent or earned by company from other financial activities.

Beam Therapeutics's other financing for the three months ended in Mar. 2020 was $-0.81 Mil. Beam Therapeutics spent $0.81 Mil on other financial activities.


Beam Therapeutics Cash Flow from Financing Related Terms


Beam Therapeutics Cash Flow from Financing Headlines

No Headline

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)